Evoke Pharma, Inc.
EVOK
$3.30
$0.216.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.25M | 8.62M | 7.53M | 6.11M | 5.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.25M | 8.62M | 7.53M | 6.11M | 5.18M |
| Cost of Revenue | 356.50K | 297.00K | 227.90K | 243.80K | 201.90K |
| Gross Profit | 9.89M | 8.32M | 7.30M | 5.86M | 4.98M |
| SG&A Expenses | 15.08M | 14.18M | 13.49M | 12.52M | 12.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.45M | 14.52M | 13.74M | 12.88M | 12.61M |
| Operating Income | -5.20M | -5.90M | -6.22M | -6.78M | -7.43M |
| Income Before Tax | -5.35M | -6.15M | -6.53M | -7.13M | -7.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.35 | -6.15 | -6.53 | -7.13 | -7.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.35M | -6.15M | -6.53M | -7.13M | -7.79M |
| EBIT | -5.20M | -5.90M | -6.22M | -6.78M | -7.43M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.27 | -11.06 | -16.21 | -22.01 | -27.97 |
| Normalized Basic EPS | -2.67 | -6.92 | -10.13 | -13.76 | -17.48 |
| EPS Diluted | -4.27 | -11.06 | -16.21 | -22.01 | -27.97 |
| Normalized Diluted EPS | -2.67 | -6.92 | -10.13 | -13.76 | -17.48 |
| Average Basic Shares Outstanding | 7.03M | 3.84M | 2.71M | 1.59M | 1.11M |
| Average Diluted Shares Outstanding | 7.03M | 3.84M | 2.71M | 1.59M | 1.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |